तुलना करने के लिए मीट्रिक्स | IDIA | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधIDIAपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −8.3x | −0.4x | −0.5x | |
PEG अनुपात | −0.13 | 0.03 | 0.00 | |
क़ीमत/बुक | −0.8x | 0.5x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 4.2x | 2.9x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 22.3% | 74.5% | 48.1% | |
उचित मूल्य अपसाइड | अनलॉक करें | 3.4% | 6.6% | अनलॉक करें |
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.